Capecitabine API

Name	Capecitabine
Chinese name	卡培他滨
Cas Number	154361-50-9
Source	India
Qualifications	USDMF/-/-/-/-

Capecitabine is a fluoropyrimidine deoxynucleoside carbamate anti-tumor drug developed by Roche, Switzerland. It was approved by the U.S. Food and Drug Safety Administration in 1998 to be marketed in the United States. It was listed in China in 2001 and in 2008. In August, the China Food and Drug Administration approved its treatment for advanced gastric cancer, and it has been widely used in many countries at home and abroad. Capecitabine is an oral fluoropyrimidine nucleoside analog with a good targeting effect, which can be selectively activated in tumor tissues to produce high concentrations of active cytotoxic substances, thereby improving the tolerance of tumor patients , And maximize anti-cancer activity. Capecitabine is the only oral fluorouracil drug approved by the FDA so far, and it is currently the most biologically active oral fluorouracil drug, which can achieve or even exceed the efficacy of other fluorouracil drugs administered intravenously. After being taken orally, capecitabine does not have the activity of killing normal cells like radical drugs. Even if it reaches various parts of the body with blood, it will not cause damage to normal cells of tissues, and it will affect normal tissues less and avoid it to a great extent. The occurrence of adverse reactions. From 2016 to 2018, the sales of anti-tumor drug hospitals increased steadily. In 2018, the sales of China's sample hospitals reached 19.070 billion yuan, a year-on-year increase of 5.26%. In 2018, the sales of capecitabine in China's sample hospitals reached 1.093 billion yuan.

Hot Tags: capecitabine api, China, suppliers, manufacturers, factory, customized, price, pricelist, in stock, Perindopril Tert butylamine Salt API, Adapalene API, Idebenone API, Bemeprost API, Fondaparinux API, Celecoxib API

• Previous: Imiquimod API
• Next: Naphazoline Hydrochloride API